(Q77071566)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10160088%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

title

Switching the histamine H2 receptor antagonist famotidine to nonprescription status in Canada. An economic evaluation (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10160088%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

1 reference

1 reference

R F Tasch

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10160088%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

R Goeree

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10160088%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

C J Henke

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10160088%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

B J O'Brien

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10160088%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

publication date

1 January 1996

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10160088%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10160088%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10160088%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10160088%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

page(s)

61-75

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10160088%20AND%20SRC:MED&resulttype=core&format=json

Reflections on a month in the life of the Ontario Drug Benefit Plan

2 December 2019

cites work

1 reference

12 December 2020

Ranitidine for non-ulcer dyspepsia. A clinical study of the symptomatic effect of ranitidine and a classification and characterization of the responders to treatment

1 reference

12 December 2020

Famotidine in gastroesophageal reflux disease (GERD)

1 reference

12 December 2020

An approach to dyspepsia in the ambulatory care setting: evaluation based on risk stratification

1 reference

12 December 2020

Over-the-counter histamine H2-receptor antagonists. How will they affect the treatment of acid-related diseases?

1 reference

12 December 2020

Self-Directed Treatment of Intermittent Heartburn: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Evaluation of Antacid and Low Doses of an H(2)-Receptor Antagonist (Famotidine).

1 reference

12 December 2020

Over-the-counter drugs. The issues

1 reference

12 December 2020

Efficacy of twice daily doses of 40 or 20 milligrams famotidine or 150 milligrams ranitidine for treatment of patients with moderate to severe erosive esophagitis. Famotidine Erosive Esophagitis Study Group

1 reference

12 December 2020

The costs and benefits of switching a drug from prescription-only to over-the-counter status: a review of methodological issues and current evidence

1 reference

12 December 2020

Cimetidine use and gastric cancer.

1 reference

12 December 2020

Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis.

1 reference

12 December 2020

Dyspepsia and dyspepsia subgroups: a population-based study

1 reference

12 December 2020

Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled, dose-ranging study. USA Merck Gastroesophageal Reflux Disease Study Group

1 reference

12 December 2020

Safety implications of the over-the-counter availability of H2-antagonists

1 reference

12 December 2020

Gastric cancer--delay in diagnosis and its causes

1 reference

12 December 2020

Famotidine (20 mg) b.d. relieves gastrooesophageal reflux symptoms in patients without erosive oesophagitis. Famotidine/GERD Investigation Group

1 reference

12 December 2020

The effect of cimetidine in non-ulcer dyspepsia. Experience with a multi-cross-over model

1 reference

12 December 2020

Dyspepsia: incidence of a non-ulcer disease in a controlled trial of ranitidine in general practice

1 reference

12 December 2020

Randomized, double-blind, placebo-controlled crossover trial of cimetidine and pirenzepine in nonulcer dyspepsia

1 reference

12 December 2020

Cimetidine responders in non-ulcer dyspepsia

1 reference

12 December 2020

Medical therapy for gastroesophageal reflux disease

1 reference

12 December 2020

Implications of placebo theory for clinical research and practice in pain management.

1 reference

12 December 2020

Pain and the placebo response

1 reference

12 December 2020

Adverse Reactions to H2-Receptor Antagonists in Denmark Before and After Transfer of Cimetidine and Ranitidine to Over-the-counter Status

1 reference

12 December 2020

Placebo response in refractory tardive akathisia.

1 reference

12 December 2020

The risks and benefits of an Rx-to-OTC switch. The case of over-the-counter H2-blockers.

1 reference

12 December 2020

Pros and cons of over-the-counter availability of histamine2-receptor antagonists

1 reference

12 December 2020

Non-ulcer dyspepsia: potential causes and pathophysiology

1 reference

12 December 2020